StockNews.com began coverage on shares of Can-Fite BioPharma (NYSE:CANF – Free Report) in a research note released on Friday morning. The brokerage issued a hold rating on the stock. Separately, HC Wainwright reaffirmed a buy rating and set a $18.00 price objective on shares of Can-Fite BioPharma in a research report on Thursday, May 9th. […]